Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 12/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 12/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | GFER | P55789 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797483 | 0.98 | CHRNB4 (0.96) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL165812 | 0.93 | CHRNB4 (0.87) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL895819 | 0.80 | CHRNB4 (0.67) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL24233984 | 0.78 | CHRNB4 (0.64) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL16098695 | 0.78 | CHRNB4 (0.66) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL8151174 | 0.78 | CHRNB4 (0.64) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| Anabaseine SCHEMBL30394330 | 0.78 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| Anabaseine SCHEMBL261062 | 0.78 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL18985115 | 0.77 | CHRNB4 (0.67) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL19253727 | 0.77 | CHRNB4 (0.63) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5686616-A | Process for preparing an optically active amine | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1997-11-11 | — | — | US | claimed |
| CN-114950558-B | Bipiperidine skeleton tetradentate nitrogen-containing manganese catalyst and method for catalyzing hydrocarbon molecule benzyl site selective oxidation by using same | 陕西师范大学 | 2023-08-11 | — | — | CN | disclosed |
| CN-114950558-A | Bipiperidine skeleton tetradentate nitrogen-containing manganese catalyst and method for catalyzing benzyl-site selective oxidation of hydrocarbon molecules by using same | 陕西师范大学 | 2022-08-30 | — | — | CN | disclosed |
| US-11389464-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2022-07-19 | — | — | US | disclosed |
| CN-109988091-B | Preparation method of imine compound | 苏州大学 | 2022-03-18 | — | — | CN | disclosed |
| EP-3719024-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | MARS, INCORPORATED | 2020-08-06 | — | — | US | disclosed |
| EP-3034509-B1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10603330-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190054101-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2019-02-21 | — | — | US | disclosed |
| WO-2002004466-A2 | CATALYST FOR ASYMMETRIC (TRANSFER) HYDROGENATION | DSM N.V. (NL) | 2002-01-17 | — | — | WO | disclosed |
| EP-1124802-A1 | PROCESS FOR PRODUCING 4-ARYLPIPERIDINE-3-CARBINOLS AND RELATED COMPOUNDS | Synthon B.V. (NL) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026187-A1 | PROCESS FOR PRODUCING 4-ARYLPIPERIDINE-3-CARBINOLS AND RELATED COMPOUNDS | SYNTHON B.V. (NL) | 2000-05-11 | — | — | WO | disclosed |
| US-5741802-A | FOR TREATMENT OF MEMORY LOSS | UNIVERSITY OF FLORIDA (US) | 1998-04-21 | — | — | US | disclosed |
| US-5734059-A | Production intermediate and process for producing pyridine derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1998-03-31 | — | — | US | disclosed |
| US-5686616-A | Process for preparing an optically active amine | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0787724-A1 | NOVEL INTERMEDIATE FOR PRODUCTION AND PROCESS FOR PRODUCING PYRIDINE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1997-08-06 | — | — | EP | disclosed |
| EP-0659078-A4 | ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM. | UNIV FLORIDA (US) | 1996-04-24 | — | — | EP | disclosed |
| EP-0659078-A1 | ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994005288-A1 | ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM | UNIVERSITY OF FLORIDA (US) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389464-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | CHRNB4 3003/4885CHRNA3 2610/4885CHRNA7 2789/4885 |
| US-10603330-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | CHRNB4 3003/4885CHRNA3 2610/4885CHRNA7 2789/4885 |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | ARG1, ARG2, PRMT1 | CHRNB4 3003/4885CHRNA3 2610/4885CHRNA7 2789/4885 |
| US-20190054101-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | CHRNB4 3003/4885CHRNA3 2610/4885CHRNA7 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.